Skip to main content

Table 5 Relative expression of mRNA levels in tumor samples after ex vivo exposure to doxorubicin. The IC50 concentrations for the samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that some technically statistically significant results could have arisen by chance.

From: Cancer cell adaptation to chemotherapy

  Breast samples Ovarian samples
Target gene n Control Doxorubicin IC50 = 0.828 μM (0.569–1.16) p n Control Doxorubicin IC50 = 1.34 μM (0.310–17.7) p
BCRP 14 0.039 0.044 0.8077 12 0.010 0.027 0.042
ERCC1 14 0.711 0.826 0.2412 11 0.440 0.506 0.4922
MDR1 14 0.069 0.056 0.0494 12 0.005 0.005 0.2036
MRP1 14 3.886 5.692 <0.0001 12 1.890 2.321 0.083
MVP 14 4.990 6.925 0.0023 12 2.251 2.687 0.042
TOPO I 14 5.464 5.128 0.0419 12 6.112 3.360 0.001
TOPO IIα 14 0.546 0.017 <0.0001 12 1.491 0.089 0.0015
TOPO IIβ 14 6.617 6.461 0.0785 12 5.907 5.252 0.0322